Alkhorayef M, Sulieman A, Mohamed-Ahmed M, Al-Mohammed H I, Alkhomashi N, Sam A K, Bradley D A
Radiological Sciences Department, College of Applied Medical Sciences, King Saud University, Riyadh, Kingdom of Saudi Arabia; Centre for Nuclear and Radiation Physics, Department of Physics, University of Surrey, Guildford, Surrey GU2 7XH, UK.
Prince Sattam Bin Abdulaziz University, College of Applied Medical Sciences, Radiology and Medical Imaging Department, Alkharj, Saudi Arabia.
Appl Radiat Isot. 2018 Nov;141:270-274. doi: 10.1016/j.apradiso.2018.07.014. Epub 2018 Jul 12.
With associated cure rates in excess of 90%, targeted I radioactive iodine therapy has clearly improved thyroid cancer survival. Thus said, potential radiation risks to staff represent a particular concern, current study seeking to determine the radiation exposure of staff from I patients during hospitalization, also estimating accumulated dose and related risk to staff during preparation of the radioactive iodine. In present study made over the three-month period 1st February to 1st May 2017, a total of 69 patient treatments were investigated (comprising a cohort of 46 females and 23 males), this being a patient treatment load typically reflective of the workload at the particular centre for such treatments. The patients were administered sodium iodide I, retained in capsules containing activities ranging from 370 to 5550 MBq at the time of calibration, radioiodine activity depends on many factors such as gender, clinical indication, body mass index and age. The staff radiation dose arising from each patient treatment was measured on three consecutive days subsequent to capsule administration. In units of µSv, the mean and dose-rates range at distances from the patients of 5 cm, 1 m and 2 m were 209 ± 73 (165-294), 6.8 ± 2 (5.3-9.5) and 0.9 ± 0.3 (0.7-1.2). The annual dose (also measured in units of µSv), based on annual records of doses, for medical physicists, technologists and nurses were 604, 680 and 1000 µSv respectively. In regard to current practice and workload, staff exposures were all found to be below the annual dose limit for radiation workers.
靶向碘 - 131放射性碘治疗的治愈率超过90%，显著提高了甲状腺癌患者的生存率。话虽如此，工作人员面临的潜在辐射风险仍是一个特别令人担忧的问题，当前的研究旨在确定工作人员在患者住院期间受到的辐射暴露情况，同时估计在放射性碘准备过程中工作人员的累积剂量及相关风险。在2017年2月1日至5月1日这三个月期间进行的本研究中，共调查了69例患者的治疗情况（包括46名女性和23名男性患者），这一患者治疗量通常反映了该特定中心此类治疗的工作量。患者接受碘化钠碘 - 131治疗，校准时刻胶囊内的活度范围为370至5550 MBq，放射性碘的活度取决于许多因素，如性别、临床指征、体重指数和年龄。在胶囊给药后的连续三天测量了每位患者治疗产生的工作人员辐射剂量。以微希沃特（µSv）为单位，在距离患者5厘米、1米和2米处的平均剂量率范围分别为209±73（165 - 294）、6.8±2（5.3 - 9.5）和0.9±0.3（0.7 - 1.2）。根据年度剂量记录，医学物理学家、技术人员和护士的年剂量（也以微希沃特为单位）分别为604、680和1000微希沃特。就当前的操作和工作量而言，发现工作人员的暴露量均低于辐射工作人员的年剂量限值。
